| PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma SM Ansell, AM Lesokhin, I Borrello, A Halwani, EC Scott, M Gutierrez, ... New England Journal of Medicine 372 (4), 311-319, 2015 | 4073 | 2015 |
| Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study AM Lesokhin, SM Ansell, P Armand, EC Scott, A Halwani, M Gutierrez, ... Journal of clinical oncology 34 (23), 2698-2704, 2016 | 1093 | 2016 |
| First-line nivolumab plus ipilimumab in advanced non–small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers N Ready, MD Hellmann, MM Awad, GA Otterson, M Gutierrez, JF Gainor, ... Journal of Clinical Oncology 37 (12), 992-1000, 2019 | 578 | 2019 |
| Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy WH Wilson, ML Grossbard, S Pittaluga, D Cole, D Pearson, N Drbohlav, ... Blood, The Journal of the American Society of Hematology 99 (8), 2685-2693, 2002 | 434 | 2002 |
| Highly effective treatment of acquired immunodeficiency syndrome–related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology RF Little, S Pittaluga, N Grant, SM Steinberg, MF Kavlick, H Mitsuya, ... Blood 101 (12), 4653-4659, 2003 | 421 | 2003 |
| Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers WH Wilson, K Dunleavy, S Pittaluga, U Hegde, N Grant, SM Steinberg, ... Journal of clinical oncology 26 (16), 2717-2724, 2008 | 409 | 2008 |
| Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies S Kummar, R Kinders, ME Gutierrez, L Rubinstein, RE Parchment, ... Journal of clinical oncology 27 (16), 2705-2711, 2009 | 389 | 2009 |
| Compressing drug development timelines in oncology using phase'0'trials S Kummar, R Kinders, L Rubinstein, RE Parchment, AJ Murgo, J Collins, ... Nature Reviews Cancer 7 (2), 131-139, 2007 | 265 | 2007 |
| Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first … HA Burris, IW Flinn, MR Patel, TS Fenske, C Deng, DM Brander, ... The Lancet Oncology 19 (4), 486-496, 2018 | 224 | 2018 |
| Drug development in oncology: classical cytotoxics and molecularly targeted agents S Kummar, M Gutierrez, JH Doroshow, AJ Murgo British journal of clinical pharmacology 62 (1), 15-26, 2006 | 217 | 2006 |
| Genomic profiling of advanced non–small cell lung cancer in community settings: gaps and opportunities ME Gutierrez, K Choi, RB Lanman, EJ Licitra, SM Skrzypczak, RP Benito, ... Clinical lung cancer 18 (6), 651-659, 2017 | 213 | 2017 |
| Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies AM Lesokhin, SM Ansell, P Armand, EC Scott, A Halwani, M Gutierrez, ... Blood, The Journal of the American Society of Hematology 124 (21), 291-291, 2014 | 208 | 2014 |
| PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a … CH Moskowitz, V Ribrag, JM Michot, G Martinelli, PL Zinzani, M Gutierrez, ... Blood 124 (21), 290, 2014 | 208 | 2014 |
| A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors A Rajan, CA Carter, RJ Kelly, M Gutierrez, S Kummar, E Szabo, ... Clinical cancer research 18 (8), 2344-2351, 2012 | 194 | 2012 |
| Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). NA Rizvi, JR Brahmer, SHI Ou, NH Segal, S Khleif, WJ Hwu, M Gutierrez, ... Journal of clinical oncology 33 (15_suppl), 8032-8032, 2015 | 186 | 2015 |
| Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH M Gutierrez, BA Chabner, D Pearson, SM Steinberg, ES Jaffe, BD Cheson, ... Journal of clinical oncology 18 (21), 3633-3642, 2000 | 179 | 2000 |
| Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy NS Azad, JB Aragon-Ching, WL Dahut, M Gutierrez, WD Figg, L Jain, ... Clinical Cancer Research 15 (4), 1411-1416, 2009 | 174 | 2009 |
| A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia R Garzon, M Savona, R Baz, M Andreeff, N Gabrail, M Gutierrez, L Savoie, ... Blood, The Journal of the American Society of Hematology 129 (24), 3165-3174, 2017 | 164 | 2017 |
| Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies S Kummar, M Gutierrez, ER Gardner, E Donovan, K Hwang, EJ Chung, ... Clinical Cancer Research 13 (18), 5411-5417, 2007 | 161 | 2007 |
| FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies V Subbiah, NO Iannotti, M Gutierrez, DC Smith, L Féliz, CF Lihou, C Tian, ... Annals of Oncology 33 (5), 522-533, 2022 | 159 | 2022 |